{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:37Z","timestamp":1792701637872,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial resistance (AMR) threatens infection management in cancer patients, yet data from sub-Saharan African oncology settings are scarce. We described the microbiology, resistance patterns and documented empirical prescribing among cancer patients with culture-confirmed infection in Rwanda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, records-based study of 297 culture-confirmed infection episodes in 286 cancer patients at King Faisal Hospital, Kigali, from 2019 to 2024. Routine susceptibility results were interpreted with the Clinical and Laboratory Standards Institute breakpoints in use at the time. Multidrug resistance (MDR) was classified with the organism-specific definitions of Magiorakos et al., which covered 232 of 254 bacterial isolates. Factors associated with MDR were examined by modified Poisson regression (adjusted prevalence ratios, aPR) with sensitivity analyses. Empirical regimens documented in the electronic medical record (EMR; 105 episodes, 100 inpatient) were compared with the WHO AWaRe framework and the 2022 Rwanda Standard Treatment Guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Urinary tract infections (UTIs) predominated (172\/297; 57.9%).\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (101\/297; 34.0%),\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      spp. (32\/297; 10.8%) and\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      spp. (25\/297; 8.4%) were the commonest isolates, and ESKAPEE pathogens accounted for 201\/297 episodes (67.7%). MDR was identified in 138 of 232 covered isolates (59.5%; 95% CI 53.1\u201365.6) and 138 of 214 classifiable isolates (64.5%; 95% CI 57.9\u201370.6); restricting to more complete panels increased the estimate. Ceftriaxone resistance was high (\n                      <jats:italic>E. coli<\/jats:italic>\n                      65\/87, 74.7%;\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      spp. 20\/29, 69.0%), and carbapenem resistance in\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      spp. was 8\/13 (61.5%). MDR prevalence did not differ by infection type (aPR versus UTI: bloodstream 0.94, 95% CI 0.67\u20131.31; skin and soft tissue 0.98, 95% CI 0.72\u20131.34) and was lower among gram-positive isolates (aPR 0.42, 95% CI 0.21\u20130.85), owing to\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      spp. Adherence of documented regimens to the national guideline was lowest for UTIs (1\/43; 2.3%). Outpatient empirical prescribing was rarely documented in the EMR and could not be evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MDR was common across all infection types, and ceftriaxone, the most frequently documented empirical agent, showed limited in vitro activity against the prevailing isolates. Whether oncology-specific empirical protocols based on local antibiograms are warranted should be evaluated prospectively, including clinical outcomes, alongside AWaRe-aligned stewardship and better documentation of prescribing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14689-2","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:56:00Z","timestamp":1792551360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial resistance and documented empirical antibiotic prescribing among cancer patients with culture-confirmed infections at a tertiary referral hospital in Rwanda, 2019\u20132024"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4041-709X","authenticated-orcid":false,"given":"Brandon Niyibizi","family":"Asuman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damas","family":"Dukundane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrigje Jacoba","family":"Kreuger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ganal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Stete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9971-522X","authenticated-orcid":false,"given":"Hajo","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-2920","authenticated-orcid":false,"given":"Vanessa M.","family":"Eichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"14689_CR1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta: Centers for Disease Control and Prevention; 2019."},{"key":"14689_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski LR, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"14689_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet. 2024;404:1199\u2013226.","journal-title":"Lancet"},{"key":"14689_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","volume-title":"Infectious complications in cancer patients. Cancer treatment and research","author":"TR Zembower","year":"2014","unstructured":"Zembower TR. Epidemiology of infections in cancer patients. In: Stosor V, Zembower TR, editors. Infectious complications in cancer patients. Cancer treatment and research. Volume 161. Cham: Springer; 2014. pp. 43\u201389."},{"key":"14689_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3904\/kjim.2016.31.1.162","volume":"31","author":"SY Park","year":"2015","unstructured":"Park SY, Kim MS, Eom JS, Lee JS, Rho YS. Risk factors and etiology of surgical site infection after radical neck dissection in patients with head and neck cancer. Korean J Intern Med. 2015;31:162\u20139.","journal-title":"Korean J Intern Med"},{"key":"14689_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/QCO.0b013e3283630c4c","volume":"26","author":"CD Alonso","year":"2013","unstructured":"Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26:326\u201331.","journal-title":"Curr Opin Infect Dis"},{"key":"14689_CR7","first-page":"825","volume":"10","author":"MB Lustberg","year":"2012","unstructured":"Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012;10:825\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"key":"14689_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(03)01218-X","volume":"4","author":"S Vento","year":"2003","unstructured":"Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol. 2003;4:595\u2013604.","journal-title":"Lancet Oncol"},{"key":"14689_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10071-23119","volume":"23","author":"VK Garg","year":"2019","unstructured":"Garg VK, Mishra S, Gupta N, Garg R, Sachidanand B, Vinod KS, et al. Microbial and antibiotic susceptibility profile among isolates of clinical samples of cancer patients admitted in the intensive care unit at regional tertiary care cancer center. Indian J Crit Care Med. 2019;23:67\u201372.","journal-title":"Indian J Crit Care Med"},{"key":"14689_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42506-023-00134-8","volume":"98","author":"N Mohamed","year":"2023","unstructured":"Mohamed N, Ghazal A, Ahmed AAH, Zaki A. Prevalence and determinants of antimicrobial resistance of pathogens isolated from cancer patients in an intensive care unit in Alexandria, Egypt. J Egypt Public Health Assoc. 2023;98:9.","journal-title":"J Egypt Public Health Assoc"},{"key":"14689_CR11","doi-asserted-by":"publisher","first-page":"e02961","DOI":"10.1128\/spectrum.02961-23","volume":"12","author":"C Lopera","year":"2024","unstructured":"Lopera C, Monz\u00f3 P, Aiello TF, Garcia-Vidal C, Chumbita M, Puerta-Alcalde P, et al. Prevalence and impact of multidrug-resistant bacteria in solid cancer patients with bloodstream infection: a 25-year trend analysis. Microbiol Spectr. 2024;12:e02961\u201323.","journal-title":"Microbiol Spectr"},{"key":"14689_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12879-020-05181-6","volume":"20","author":"AM Jiang","year":"2020","unstructured":"Jiang AM, Shi X, Liu N, Zhu H, Yang C, Bai H, et al. Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology center in Western China. BMC Infect Dis. 2020;20:452.","journal-title":"BMC Infect Dis"},{"key":"14689_CR13","first-page":"488","volume":"71","author":"AK Nanayakkara","year":"2021","unstructured":"Nanayakkara AK, Boucher HW, Fowler VG Jr, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: escalating challenges and paths forward. CA Cancer J Clin. 2021;71:488\u2013504.","journal-title":"CA Cancer J Clin"},{"key":"14689_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/microorganisms7090277","volume":"7","author":"EIA Perdikouri","year":"2019","unstructured":"Perdikouri EIA, Arvaniti K, Lathyris D, Koulourida V, Apostolidou-Kiouti F, Siskou E, et al. Infections due to multidrug-resistant bacteria in oncological patients: insights from a five-year epidemiological and clinical analysis. Microorganisms. 2019;7:277.","journal-title":"Microorganisms"},{"key":"14689_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4269\/ajtmh.14-0607","volume":"92","author":"C Ntirenganya","year":"2015","unstructured":"Ntirenganya C, Manzi O, Muvunyi CM, Ogbuagu O. High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda. Am J Trop Med Hyg. 2015;92:865\u201370.","journal-title":"Am J Trop Med Hyg"},{"key":"14689_CR16","volume-title":"The WHO AWaRe (Access, Watch, Reserve) antibiotic book","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 1st ed. Geneva: World Health Organization; 2022.","edition":"1"},{"key":"14689_CR17","volume-title":"Rwanda Standard Treatment Guidelines: the guideline for the use of antibiotics in Rwanda","author":"Ministry of Health, Rwanda","year":"2022","unstructured":"Ministry of Health, Rwanda. Rwanda Standard Treatment Guidelines: the guideline for the use of antibiotics in Rwanda. Kigali: Ministry of Health; 2022."},{"key":"14689_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/antibiotics13111032","volume":"13","author":"A Igizeneza","year":"2024","unstructured":"Igizeneza A, Bitunguhari L, Masaisa F, Uwimana M, Sebatunzi O, Mvukiyehe JP, et al. Prescription practices and usage of antimicrobials in a tertiary teaching hospital in Rwanda: a call for antimicrobial stewardship. Antibiot (Basel). 2024;13:1032.","journal-title":"Antibiot (Basel)"},{"key":"14689_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12879-017-2713-1","volume":"17","author":"BT Tadesse","year":"2017","unstructured":"Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wiber M, Lester R, et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17:616.","journal-title":"BMC Infect Dis"},{"key":"14689_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/antibiotics13070659","volume":"13","author":"L Gahimbare","year":"2024","unstructured":"Gahimbare L, Muvunyi CM, Guessennd NAK, Musabyimana JP, Ndayisaba GF, Niyonzima FN, et al. Antimicrobial resistance in the World Health Organization African region: a systematic literature review 2016\u20132020. Antibiot (Basel). 2024;13:659.","journal-title":"Antibiot (Basel)"},{"key":"14689_CR21","first-page":"GO2000281","volume":"6","author":"F Rubagumya","year":"2020","unstructured":"Rubagumya F, Costas-Chavarri A, Manirakiza A, Murenzi G, Uwizeye FR, Shyirambere C, et al. State of cancer control in Rwanda: past, present, and future opportunities. JCO Glob Oncol. 2020;6:GO2000281.","journal-title":"JCO Glob Oncol"},{"key":"14689_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"14689_CR23","volume-title":"National cancer control plan 2020\u20132024","author":"Rwanda Biomedical Centre","year":"2020","unstructured":"Rwanda Biomedical Centre. National cancer control plan 2020\u20132024. Kigali: Rwanda Biomedical Centre; 2020."},{"key":"14689_CR24","doi-asserted-by":"publisher","first-page":"e0221121","DOI":"10.1371\/journal.pone.0221121","volume":"14","author":"T Sutherland","year":"2019","unstructured":"Sutherland T, Mpirimbanyi C, Nziyomaze E, Niyibizi G, Niyonsenga Z, Nzarora B, et al. Widespread antimicrobial resistance among bacterial infections in a Rwandan referral hospital. PLoS ONE. 2019;14:e0221121.","journal-title":"PLoS ONE"},{"key":"14689_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3126\/ajms.v11i6.29921","volume":"11","author":"MJ Bosco","year":"2020","unstructured":"Bosco MJ, Jonas B, Evelyne K, Pauline K. Urinary tract infection and antimicrobial resistance profile in patients attending Nemba District Hospital in Rwanda. Asian J Med Sci. 2020;11:101\u20135.","journal-title":"Asian J Med Sci"},{"key":"14689_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/IDR.S299520","volume":"14","author":"T Habyarimana","year":"2021","unstructured":"Habyarimana T, Murenzi D, Musoni E, Yadufashije C, Niyonzima FN. Bacteriological profile and antimicrobial susceptibility patterns of bloodstream infection at Kigali University Teaching Hospital. Infect Drug Resist. 2021;14:699\u2013707.","journal-title":"Infect Drug Resist"},{"key":"14689_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13104-019-4520-9","volume":"12","author":"M Lubwama","year":"2019","unstructured":"Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu JB, et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes. 2019;12:464.","journal-title":"BMC Res Notes"},{"key":"14689_CR28","doi-asserted-by":"publisher","first-page":"e0266919","DOI":"10.1371\/journal.pone.0266919","volume":"17","author":"M Worku","year":"2022","unstructured":"Worku M, Belay G, Tigabu A. Bacterial profile and antimicrobial susceptibility patterns in cancer patients. PLoS ONE. 2022;17:e0266919.","journal-title":"PLoS ONE"},{"key":"14689_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12879-020-4886-2","volume":"20","author":"F Chinowaita","year":"2020","unstructured":"Chinowaita F, Chaka W, Nyazika TK, Nziramasanga P, Mhangara M, Nkavulu L, et al. Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns. BMC Infect Dis. 2020;20:161.","journal-title":"BMC Infect Dis"},{"key":"14689_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12879-025-10481-w","volume":"25","author":"OK Ntim","year":"2025","unstructured":"Ntim OK, Awere-Duodu A, Osman AH, Donkor ES. Antimicrobial resistance of bacterial pathogens isolated from cancer patients: a systematic review and meta-analysis. BMC Infect Dis. 2025;25:296.","journal-title":"BMC Infect Dis"},{"key":"14689_CR31","doi-asserted-by":"publisher","first-page":"e1004638","DOI":"10.1371\/journal.pmed.1004638","volume":"22","author":"G Osena","year":"2025","unstructured":"Osena G, Kapoor G, Kalanxhi E, Oyston J, Klein EY. Antimicrobial resistance in Africa: a retrospective analysis of data from 14 countries, 2016\u20132019. PLoS Med. 2025;22:e1004638.","journal-title":"PLoS Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14689-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:03:04Z","timestamp":1792699384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14689"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14689-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Institutional Review Board of King Faisal Hospital (protocol KFH\/2025\/291\/IRB) and the Ethics Committee of the University of Freiburg (reference EK-Freiburg 25\u22121122-S2). Given the retrospective, pseudonymised nature of the dataset, the requirement for individual written informed consent was waived by both ethics committees.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No individually identifying information is presented in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1865"}}